The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended new medicines from Hansoh, Innovent, and AstraZeneca during its November review cycle, according to BIOCENTURY reporting. Two out of three recommended therapies originated from China-based originators at the committee’s meeting. The CHMP’s positive opinion is a key regulatory milestone that typically precedes potential European Commission authorization, with branded and pipeline developers using the committee action to advance launch planning and label strategy across EU markets. The update underscores how late-stage regulatory momentum continues to concentrate around a small set of originators receiving CHMP backing at the same committee meeting.